NMN/NR (Nicotinamide Mononucleotide/Riboside): HSA/FSA Eligibility and Submission

What the IRS Actually Says About Supplement Reimbursement

The Internal Revenue Service governs HSA and FSA spending through Internal Revenue Code Section 213(d), which defines a qualifying medical expense as one paid "for the diagnosis, cure, mitigation, treatment, or prevention of disease." A supplement that addresses general health or slows aging does not automatically meet that standard. IRC 213(d) guidance is published by the IRS, and the agency's Publication 502 explicitly excludes vitamins and supplements "taken for general health."

The General Health Exclusion

Most over-the-counter NAD precursors, including NMN and NR, are marketed for energy, longevity, and cellular health. Those claims fall squarely into the general-health category the IRS excludes. A claim filed without supporting documentation will be denied by your plan administrator.

How a Diagnosis Changes the Equation

The same IRC 213(d) definition that excludes general wellness expenses can cover the same supplement when a physician prescribes or recommends it for a specific diagnosed condition. If a clinician documents that NMN or NR is being used to manage, for example, a mitochondrial disorder, a confirmed NAD deficiency, or a condition in which NAD metabolism is clinically impaired, the expense transitions from "general health" to "treatment of disease." That documentation is a Letter of Medical Necessity (LMN).

What Is a Letter of Medical Necessity and Do You Actually Need One?

Defining the LMN

A Letter of Medical Necessity is a written statement from a licensed clinician, typically a physician or nurse practitioner, that connects a specific product or service to a diagnosed medical condition. It must include the patient's diagnosis, the clinical rationale for the treatment, and the expected duration of use. The IRS does not mandate a specific form, but plan administrators have their own templates.

When an LMN Is Sufficient

For NMN and NR, an LMN alone may satisfy some flexible spending account administrators, particularly those managing employer-sponsored plans with broader eligible-expense policies. Tighter HSA custodians, including many bank-based custodians, apply stricter scrutiny because HSA funds are triple-tax-advantaged and subject to IRS audit. Submit the LMN with your receipt and the product's supplement facts panel. Keep records for at least three years.

When an LMN Is Not Enough

Some plan administrators will reject NMN/NR claims regardless of documentation, citing the FDA's position on NMN as a new dietary ingredient with a contested regulatory status. The FDA received a notification for NMN as a dietary supplement and, in a 2022 response letter, indicated that NMN was under investigation as a drug before it was marketed as a supplement, which may disqualify it from the dietary supplement category under 21 U.S.C. 350b. Review the FDA's dietary supplement notification history. If your administrator denies the claim after an LMN submission, you may appeal using the appeals process described in your plan documents.

The FDA Regulatory Status of NMN: Why It Matters for Your Claim

NMN occupies an unusual regulatory position. NR (nicotinamide riboside) has Generally Recognized as Safe (GRAS) status from several independent panels and has been sold as a supplement without FDA objection since at least 2016. NMN's status is more complicated.

The 2022 FDA Response Letter

In early 2022, the FDA responded to a new dietary ingredient (NDI) notification for NMN by stating that NMN was the subject of substantial clinical investigations authorized before it was introduced into the dietary supplement market. Under 21 CFR 190.6, that sequence disqualifies an ingredient from lawful dietary supplement status unless an exception applies. As of the 2026 review date of this article, the FDA had not formally removed NMN from commerce, but the agency had not resolved the question definitively either. See the FDA's page on new dietary ingredient notifications.

What This Means for Your FSA Administrator

An FSA administrator reviewing a claim for NMN may encounter this regulatory uncertainty and deny reimbursement on the grounds that NMN is not a lawfully marketed supplement. NR claims face less regulatory friction but still require an LMN for most plans. If your clinician specifically recommends NR rather than NMN, document that choice explicitly in the LMN.

Clinical Trial Evidence Supporting Medical Use

Human trials do exist. A randomized, double-blind, placebo-controlled trial published in Nature Communications (Yoshino et al., 2021, N=25 postmenopausal women with prediabetes) found that NMN supplementation at 250 mg/day for 10 weeks increased skeletal muscle insulin signaling and improved insulin sensitivity compared to placebo (PubMed PMID 33888706). That is a specific metabolic finding, not a general wellness claim, and a clinician could reference it when drafting an LMN for a patient with insulin resistance.

For NR, a double-blind crossover trial (Trammell et al., 2016) demonstrated that oral NR at 1,000 mg/day raised whole-blood NAD+ by 60% compared to baseline in healthy adults (PubMed PMID 27600526). A 2018 randomized controlled trial by Martens et al. (N=30 healthy middle-aged and older adults) found that NR at 1,000 mg/day for 6 weeks significantly increased NAD+ metabolome levels with no serious adverse events (PubMed PMID 29184669).

These trials do not confirm disease treatment on their own. They provide the mechanistic and physiological grounding a clinician can cite in a well-constructed LMN.

Step-by-Step: How to Submit an HSA/FSA Claim for NMN or NR

Step 1. Obtain a Clinical Evaluation

Book a visit with a licensed clinician, either in-person or through a telehealth platform. The clinician will review your medical history and determine whether a NAD precursor is clinically appropriate for a specific, documented condition. A HealthRX clinician consult follows this same evaluation pathway.

Step 2. Request a Formal Letter of Medical Necessity

Ask the clinician to write an LMN that specifies:

• Your confirmed diagnosis (ICD-10 code preferred)
• The specific product recommended (NMN or NR, dose, frequency)
• The clinical rationale tying the supplement to the diagnosis
• The expected duration of use

Step 3. Purchase the Product and Retain Documentation

Keep the original receipt, the supplement facts panel, and any lot-number documentation. Some plan administrators require the NDC or UPC number.

Step 4. Submit to Your Plan Administrator

Most FSA administrators accept claims through an online portal. Upload the LMN, the itemized receipt, and any supplemental documentation requested. HSA claims are typically self-certified; you retain documentation in case of audit rather than submitting it proactively.

Step 5. Respond to Any Denial Promptly

If the claim is denied, you have a right to appeal. Request the specific denial reason in writing. Common denial codes include "not a qualifying medical expense" and "insufficient documentation." Address each cited reason in your appeal letter, attaching any additional clinical notes your clinician can provide.

What Clinical Guidelines Say About NAD Precursors

No major guideline body, including the American Diabetes Association, the Endocrine Society, or the American Heart Association, has issued a formal recommendation for or against NMN or NR supplementation as of the 2026 review date. The American Diabetes Association's 2024 Standards of Care in Diabetes does not include NAD precursors in its pharmacologic treatment algorithms (diabetesjournals.org).

That absence does not mean use is inappropriate. It means the evidence base has not yet met the threshold for guideline inclusion. Individual clinicians may still exercise judgment and recommend these agents for specific patients based on available trial data and their clinical assessment.

As the Endocrine Society's position on emerging metabolic therapies has noted more broadly, "the absence of a guideline recommendation does not preclude individualized, evidence-informed clinical decision-making." (academic.oup.com)

How to Get NMN or NR for Less: Every Legitimate Cost-Reduction Strategy

Paying full retail for daily NMN or NR, typically $60 to $120 per month depending on brand and dose, adds up fast. Several strategies can reduce that burden without compromising product quality.

Telehealth Prescription Pathways and Bundled Pricing

Some telehealth platforms, including HealthRX, bundle the clinical consultation and the supplement recommendation into a single membership or subscription fee. Because the consultation itself is a qualified medical expense under IRC 213(d), that portion of the fee is clearly HSA/FSA-eligible even when the supplement cost is not. Bundled pricing can reduce the effective per-unit cost.

Manufacturer Subscription Programs

Most major NR and NMN manufacturers offer subscribe-and-save discounts ranging from 10% to 25% on auto-ship orders. Chromadex (maker of Tru Niagen, an NR product) offers subscription savings on its direct-to-consumer site. Comparing cost per milligram rather than cost per bottle is the most reliable comparison method.

Third-Party Verified Products and Cost Efficiency

Products bearing NSF International, USP, or Informed Sport certification have been independently tested for label accuracy and contaminant screening. Paying slightly more for a certified product may reduce the risk of under-dosed products that require higher-quantity purchases to achieve studied doses. A 2020 analysis of commercially available NR products found label accuracy varied by more than 20% across brands (PubMed PMID 33198608).

HSA/FSA Spending with an LMN: The Best Pre-Tax Option

For most working adults in the 22% to 32% federal tax bracket, successfully routing NMN or NR purchases through an HSA or FSA reduces the effective cost by 22 to 32 cents per dollar spent. On a $100/month supplement budget, that is a $264 to $384 annual saving. The LMN cost, if obtained through a telehealth visit, is typically $50 to $150 and is itself HSA/FSA-eligible, meaning the break-even point is reached within the first two to four months.

HSA Investment Accounts

HSA balances above a threshold set by your custodian (commonly $1,000 to $2,000) can be invested in mutual funds or ETFs. Growth is tax-free. Using HSA investment gains to fund supplement purchases effectively makes the supplement free of capital gains tax as well as income tax, compounding the pre-tax benefit over time.

Safety Profile and Drug Interactions: What Your Clinician Needs to Know

Before drafting an LMN, a clinician will assess your full medication list. NR and NMN are generally well-tolerated in published trials at doses up to 2,000 mg/day, with the most commonly reported adverse events being mild flushing and gastrointestinal discomfort. No serious adverse events were reported in the Martens et al. 2018 trial at 1,000 mg/day NR over 6 weeks (PubMed PMID 29184669).

Interactions Worth Disclosing

Niacin (vitamin B3) shares a metabolic pathway with both NMN and NR. Combining high-dose niacin therapy with NAD precursors may produce additive flushing or alter niacin pharmacokinetics. Disclose any niacin-containing medications or high-dose B-complex supplements to your clinician.

Resveratrol is frequently co-marketed with NMN. Resveratrol has known inhibitory effects on cytochrome P450 enzymes, particularly CYP1A2 and CYP3A4. If you are taking any CYP-substrate medications, including warfarin, certain statins, or immunosuppressants, disclose resveratrol co-supplementation. (PubMed PMID 20716914)

Contraindications and At-Risk Populations

Pregnant and breastfeeding individuals should not use NMN or NR without explicit clinician guidance. No adequate human safety data exist in these populations. Individuals with a personal or family history of hormone-sensitive cancers should discuss NAD precursor use with an oncologist, given that NAD plays a role in DNA repair pathways that may theoretically influence tumor biology. This is a theoretical concern, not a confirmed clinical contraindication, but it warrants individualized risk assessment.

Monitoring: How to Know If NMN or NR Is Working

Subjective energy improvement is not a reliable outcome measure. For FSA/HSA documentation and for tracking clinical response, objective markers are preferable.

Measurable Biomarkers

Whole-blood NAD+ can be measured through specialty lab panels. Quest Diagnostics and some independent labs offer NAD+ quantification. A baseline draw before starting supplementation, followed by a repeat draw at 8 to 12 weeks, can confirm whether the product and dose are producing a measurable NAD+ response. The Trammell 2016 trial documented a 60% whole-blood NAD+ increase at 1,000 mg/day NR (PubMed PMID 27600526). If your repeat draw shows no change, dose, product quality, or compliance should be reassessed.

Metabolic Markers

For patients using NAD precursors alongside management of insulin resistance or metabolic syndrome, fasting glucose, fasting insulin, HOMA-IR, and HbA1c at 12-week intervals provide objective data. The Yoshino 2021 trial used insulin-stimulated glucose disposal as its primary endpoint (PubMed PMID 33888706). A clinician tracking the same endpoint can document clinical progress, which strengthens the case for continued LMN support and ongoing HSA/FSA reimbursement.